{"id":87147,"date":"2019-01-29T08:42:20","date_gmt":"2019-01-29T16:42:20","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2019\/01\/unity-expands-human-senolytic-trial"},"modified":"2019-01-29T08:42:20","modified_gmt":"2019-01-29T16:42:20","slug":"unity-expands-human-senolytic-trial","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2019\/01\/unity-expands-human-senolytic-trial","title":{"rendered":"UNITY Expands Human Senolytic Trial"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/unity-expands-human-senolytic-trial.jpg\"><\/a><\/p>\n<p>UNITY Biotechnologies has recently announced an expansion of its first-stage human trial of UBX0101, a drug that has been shown to have senolytic properties in mice [1] and that the company hopes will be useful in treating painful osteoarthritis of the knee.<\/p>\n<p><strong>An expanded clinical trial<\/strong><\/p>\n<p>UNITY Biotechnologies, a $495 million biotech company in the process of creating <a href=\"https:\/\/www.leafscience.org\/what-are-senolytics\/\">senolytic<\/a> medicines that <a href=\"https:\/\/www.leafscience.org\/hallmarks-of-aging-cellular-senescence\/\">target one of the aging processes<\/a>, has just <a href=\"https:\/\/www.apnews.com\/1148adad1993c788e6de57111bf95185\">announced<\/a> an expansion of its first-stage human <a href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/record\/NCT03513016?term=NCT03513016&rank=1&view=record\">trial<\/a> of the first drug in its pipeline (UBX0101), which targets painful osteoarthritis of the knee.<\/p>\n<p><!-- Link: <a href=\"https:\/\/www.leafscience.org\/unity-expands-human-senolytic-trial\/\">https:\/\/www.leafscience.org\/unity-expands-human-senolytic-trial\/<\/a> --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>UNITY Biotechnologies has recently announced an expansion of its first-stage human trial of UBX0101, a drug that has been shown to have senolytic properties in mice [1] and that the company hopes will be useful in treating painful osteoarthritis of the knee. An expanded clinical trial UNITY Biotechnologies, a $495 million biotech company in the [\u2026]<\/p>\n","protected":false},"author":370,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,269],"tags":[],"class_list":["post-87147","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-life-extension"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/87147","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/370"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=87147"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/87147\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=87147"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=87147"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=87147"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}